GlassScriptPhysician profile
Alice V Lilly
NPI 1972067395
$8,503.30
in general payments reported to CMS, 2019-2025
43 companies · $2,194 in 2025
The $2,194 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,393 · 2022: $1,880 · 2023: $489 · 2024: $1,547 · 2025: $2,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,230.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $768.23 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Abbvie INC. | $754.52 | 2023-2025 | |
| Csl Behring | $716.47 | 2021-2023 | Hizentra |
| Astrazeneca Pharmaceuticals LP | $675.25 | 2021-2022 | |
| Genzyme Corporation | $550.25 | 2021-2025 | |
| Glaxosmithkline, LLC. | $546.20 | 2021-2022 | |
| Ucb, INC. | $528.03 | 2023-2025 | Briviact, Nayzilam, Rystiggo |
| Neurelis, INC. | $460.15 | 2023-2025 | Valtoco |
| Regeneron Healthcare Solutions, INC. | $302.54 | 2021-2022 | |
| Gilead Sciences, INC. | $294.85 | 2024-2025 | Livdelzi, Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $284.14 | 2023-2025 | Xifaxan, Plenvu |
| Kaleo, INC. | $252.27 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $212.99 | 2024-2025 | Zenpep |
| Octapharma USA, INC. | $180.72 | 2021-2022 | |
| Lundbeck LLC | $167.43 | 2023-2025 | Vyepti |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $156.69 | 2024-2025 | Voquezna |
| Amgen INC. | $141.21 | 2022 | |
| Alexion Pharmaceuticals, INC. | $139.74 | 2023-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $139.56 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $136.83 | 2024-2025 | Ingrezza |
| Janssen Biotech, INC. | $128.05 | 2024-2025 | Tremfya, Stelara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.30 | 2021-2022 | |
| Argenx US, INC. | $107.11 | 2024-2025 | Vyvgart |
| Sk Life Science, INC. | $89.29 | 2023-2025 | |
| Lilly USA, LLC | $83.24 | 2023-2025 | Emgality, Reyvow, Omvoh |
| Ardelyx, INC. | $83.12 | 2024-2025 | Ibsrela |
| Jazz Pharmaceuticals INC. | $59.21 | 2025 | |
| Grifols USA, LLC | $58.95 | 2021-2022 | |
| Sandoz INC. | $45.00 | 2024 | Hyrimoz |
| Daiichi Sankyo INC. | $38.85 | 2025 | Injectafer |
| Redhill Biopharma INC. | $36.31 | 2023-2024 | Talicia |
| Boston Scientific Corporation | $31.99 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $29.99 | 2025 | Acthar |
| Fresenius Kabi USA, LLC | $28.55 | 2024 | Idacio |
| Amneal Pharmaceuticals LLC | $22.35 | 2025 | Crexont |
| Horizon Therapeutics Plc | $20.30 | 2021 | |
| Novo Nordisk INC | $19.31 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $17.11 | 2025 | |
| Genentech USA, INC. | $16.76 | 2021 | |
| Biocryst US Sales Co., LLC | $15.76 | 2022 | |
| Celltrion USA INC. | $15.74 | 2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $13.18 | 2023 | Dificid |
| Hospira, INC. | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Lilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.